Intratect
Intratect is a sterile solution of human normal immunoglobulin (IgG) for intravenous administration. It contains a broad spectrum of antibodies against various infectious agents, purified from plasma of human donors.
Dosage by Body Weight
Administered strictly via intravenous infusion by a healthcare professional. Dosage is highly individualized and calculated based on the patient's body weight, clinical indication, and immunological response.
- Body Weight
- Below 5 kg
- Dose
- 1.6 to 3.2 g (based on 0.4 - 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Calculated strictly on precise body weight and clinical indication. Administered in a hospital setting.
- Body Weight
- 5-7 kg
- Dose
- 2.0 to 5.6 g (based on 0.4 - 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Adjusted based on clinical response and trough IgG levels.
- Body Weight
- 8-10 kg
- Dose
- 3.2 to 8.0 g (based on 0.4 - 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Adjusted based on clinical response and trough IgG levels.
- Body Weight
- 11-15 kg
- Dose
- 4.4 to 12.0 g (based on 0.4 - 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Adjusted based on clinical response and trough IgG levels.
- Body Weight
- 16-20 kg
- Dose
- 6.4 to 16.0 g (based on 0.4 - 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Adjusted based on clinical response and trough IgG levels.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 1.6 to 3.2 g (based on 0.4 - 0.8 g/kg) | Every 3 to 4 weeks | Calculated strictly on precise body weight and clinical indication. Administered in a hospital setting. |
| 5-7 kg | 2.0 to 5.6 g (based on 0.4 - 0.8 g/kg) | Every 3 to 4 weeks | Adjusted based on clinical response and trough IgG levels. |
| 8-10 kg | 3.2 to 8.0 g (based on 0.4 - 0.8 g/kg) | Every 3 to 4 weeks | Adjusted based on clinical response and trough IgG levels. |
| 11-15 kg | 4.4 to 12.0 g (based on 0.4 - 0.8 g/kg) | Every 3 to 4 weeks | Adjusted based on clinical response and trough IgG levels. |
| 16-20 kg | 6.4 to 16.0 g (based on 0.4 - 0.8 g/kg) | Every 3 to 4 weeks | Adjusted based on clinical response and trough IgG levels. |
Formulation
Purpose
Used as replacement therapy in patients with primary and secondary immunodeficiency syndromes, and for immunomodulation in autoimmune conditions such as primary immune thrombocytopenia (ITP), Guillain-Barré syndrome, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy (CIDP).
Generic Name
Human normal immunoglobulinScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.